Human Genetics Market Analysis

Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment)

The diagnostics & treatment segment is expected to hold a share of 46.7% through 2037 due to the growing demand for precise diagnosis and personalized treatment options. This is attributed to the advancement of genetic testing, which provides essential insights into patient management. In July 2023, Quest Diagnostics launched Genetic Insights, which provides health reports tailored to an individual's genes, further cementing the need to enable early detection and preventive care in this segment. This trend reflects an increasing role of diagnostics in improving healthcare outcomes.

Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others)

In human genetics market, Non-Invasive Prenatal Testing (NIPT) segment is set to capture revenue share of over 35% by 2037 due to the growing demand for safe prenatal diagnosis. NIPT facilitates early detection of genetic disorders in the fetus, offering vital importance in prenatal care. For instance, in July 2023, Optical Genome Mapping, an advanced technology for next-generation genetic testing, was introduced by a team of scientists from the Centre for Cellular and Molecular Biology, India. This development underlines the increase in the usage of complex genetic testing methodologies, thereby driving the demand for NIPT during the forecast period.

Our in-depth analysis of the human genetics market includes the following segments: